Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 11/20 | 0.71 |
| ▸ | ABL1 | P00519 | 7/20 | 0.71 |
| ▸ | EGFR | P00533 | 7/20 | 0.71 |
| ▸ | ABL2 | P42684 | 7/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 8/20 | 0.69 |
| ▸ | LCK | P06239 | 4/20 | 0.63 |
| ▸ | TEK | Q02763 | 2/20 | 0.63 |
| ▸ | HCK | P08631 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8098888 | 0.95 | SRC (0.65) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL7019630 | 0.90 | SRC (0.81) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL8112551 | 0.90 | SRC (0.73) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL8108273 | 0.87 | SRC (0.70) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL8114235 | 0.87 | SRC (0.71) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL7017930 | 0.86 | SRC (0.68) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL7018756 | 0.86 | SRC (0.65) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL7023975 | 0.85 | EGFR (0.76) | SRCABL1EGFRABL2LCK | |
| SCHEMBL8108644 | 0.84 | SRC (0.67) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL8098913 | 0.83 | SRC (0.63) | SRCABL1EGFRABL2RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6051577-A | TYROSINE INHIBITORS; BONE DISORDERS | NOVARTIS AG (CH) | 2000-04-18 | — | — | US | disclosed |